Synthesis and biological evaluation of novel pyrimidine–benzimidazol hybrids as potential anticancer agents

Synthesis and evaluation of novel $N,N'$-disubstituted benzimidazolium bromides salts as antitumor agents

“…Shortly, 15 × 10 3 prostate and ovarian cancer cells were plated in triplicate in 96-well flat bottom tissue culture plates, and treated with DMSO (for positive control group) and different concentrations (1,5,25,50, and 100 µ M) of benzimidazole compounds (1-7) in DMSO; then cells were incubated for 24 and 48 h at 37…”

Zinc Triflate Promoted General Synthetic Protocol for the Facile Construction of Chromenes and Pyrimidines Bearing N-Allyl Quinolone Nucleus

“…1 H NMR and 13 C NMR spectra were recorded in DMSO-d 6 and CDCl 3 on a Bruker Avance 400F (MHz) spectrometer (Bruker Scientific Corporation Ltd., Switzerland) using TMS as an internal standard at 400 MHz and 100 MHz respectively. Chemical shifts are reported in parts per million (ppm).…”

“…Fused chromenes compounds possesses wide spectrum of activities such as antibacterial [1], anticancer agents [2], anti-rhinovirus activity [3], antipyretic, analgesic, anti-inflammatory and antioxidant activities [4]. Pyrimidines are an important class of the heterocyclic compounds possesses various therapeutic and pharmacological properties, like anti-inflammatory and antimicrobial agents [5], anticancer agents [6], antitubercular and antimicrobial activities [7] and antimalarial activity [8].…”

Synthesis and anticancer activity of novel tetrahydroquinoline and tetrahydropyrimidoquinoline derivatives

“…It was reported also that a large number of quinolines and their derivatives possessed potent anticancer activity (Chen et al, 2005a(Chen et al, , b, 2006Zhao et al, 2005;Li et al, 2006;Tseng et al, 2008Tseng et al, , 2012Al-Said et al, 2011;Luniewski et al 2012;Karthikeyan et al, 2015). Several studies supported that the pyrimidine nucleus is an important pharmacophore in various antitumor agents (Ghorab et al, 1996(Ghorab et al, , 2006aGhorab, 2000;Abou El Ella et al, 2008;Liu et al, 2014;Shao et al, 2014;Kandeel et al, 2015;Ma et al, 2015). Moreover, it is present in potent marketed anticancer drugs, for example, gefitinib (Iressa TM ) (Wakeling et al, 2002) and erlotinib (Tarceva TM ) (Moyer et al, 1997), and thus, it is considered as attractive target for the design of new anticancer agents.…”